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Abstract
Background: Oral anticoagulant therapy (OAT) with warfarin is the standard of stroke prevention in patients with atrial
fibrillation. Approximately 30% of patients with cardioembolic strokes are on OAT at the time of symptom onset. We
investigated whether warfarin exacerbates the risk of thrombolysis-associated hemorrhagic transformation (HT) in a mouse
model of ischemic stroke.
Methods: 62 C57BL/6 mice were used for this study. To achieve effective anticoagulation, warfarin was administered orally.
We performed right middle cerebral artery occlusion (MCAO) for 3 h and assessed functional deficit and HT blood volume
after 24 h.
Results: In non-anticoagulated mice, treatment with rt-PA (10 mg/kg i.v.) after 3 h MCAO led to a 5-fold higher degree of HT
compared to vehicle-treated controls (4.060.5 ml vs. 0.860.1, p,0.001). Mice on warfarin revealed larger amounts of HT
after rt-PA treatment in comparison to non-anticoagulated mice (9.263.2 ml vs. 2.861.0, p,0.05). The rapid reversal of
anticoagulation by means of prothrombin complex concentrates (PCC, 100 IU/kg) at the end of the 3 h MCAO period, but
prior to rt-PA administration, neutralized the exacerbated risk of HT as compared to sham-treated controls (3.860.7 ml vs.
15.063.8, p,0.001).
Conclusion: In view of the vastly increased risk of HT, it seems to be justified to withhold tPA therapy in effectively
anticoagulated patients with acute ischemic stroke. The rapid reversal of anticoagulation with PCC prior to tPA application
reduces the risk attributed to warfarin pretreatment and may constitute an interesting therapeutic option.
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Introduction
Intravenous thrombolysis with recombinant tissue plasminogen
activator (rt-PA) reduces death and disability when administered
within the first 4.5 h after symptom onset in patients with ischemic
stroke, although the pooled data of the large thrombolysis in stroke
trials (ECASS, ATLANTIS, NINDS, and EPITHET) revealed
that the risk of symptomatic intracerebral hemorrhage is
considerably elevated in rt-PA patients (5.2%) as compared to
controls (1.0%) [1]. In general, hemorrhagic transformation (HT)
of ischemic brain tissue after rt-PA therapy is frequently observed
and can be graded into hemorrhagic infarction (petechial infarct
without space-occupying effect) or parenchymal hematoma
(hemorrhage with mass effect) [2].
It is believed that the risk of HT is increased in patients with a
compromised blood coagulation system. Therefore, the AHA
guidelines for the management of stroke recommend withholding
thrombolysis with from patients being under oral anticoagulant
therapy (OAT) with an international normalized ratio (INR).1.7
[3]. However, there are only few clinical and no experimental data
to substantiate the assumption that effective warfarin treatment
exacerbates the risk of thrombolysis-associated intracerebral
hemorrhage. While it is widely accepted that patients with a
compromised blood coagulation system due to effective anticoag-
ulation or a hemostatic disorder should not be treated with
systemic thrombolysis, the issue is less clear for patients with
subtherapeutic INR values. A recent, vividly debated report on
107 warfarin-treated stroke patients who were eligible for rt-PA
treatment due to subtherapeutic INR values of ,1.7 showed an
increased rate of symptomatic intracerebral hemorrhage in the
warfarin-treated group after thrombolysis even after multivariate
adjustment for the relevant covariates age, atrial fibrillation, initial
stroke severity by the National Institutes of Health Stroke Scale,
and INR [4]. A large observational study assessing the influence of
antithrombotic pretreatment on stroke severity in patients with
ischemic stroke and atrial fibrillation found no difference in the
frequency of spontaneous secondary intracranial hemorrhage in
the warfarin-treated group compared to the group not receiving
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of hemorrhagic transformation secondary to thrombolysis in the
anticoagulated group was much higher compared with the
antiplatelet-treated and antithrombotic-naı ¨ve patients [6].
Based on a mouse model of focal cerebral ischemia, we have
recently shown that large hemispheric infarctions evolving under
effective warfarin treatment reveal significantly enlarged amounts
of HT as compared to those evolving under normal coagulation.
This applies to both the upper and the lower end of the
therapeutic INR range [7]. The present study investigates whether
thrombolytic treatment with i.v. rt-PA further exacerbates the risk
of HT in warfarin-anticoagulated mice, with the aim to gain in vivo
evidence for the widespread practice to withhold thrombolysis in
anticoagulated stroke patients. Furthermore, we evaluated wheth-
er the rapid reversal of anticoagulation using prothrombin
complex concentrates (PCC) just before rt-PA administration
reduces the risk of excess HT caused by effective warfarin
treatment.
Results
Both treatment with rt-PA and effective oral
anticoagulation harbor a significant risk of hemorrhagic
transformation
After 3 h MCAO, leading to ischemic lesions of
111.6635.4 mm
3 in our hands (n=6, data not shown), the
extent of HT in untreated animals was found to be very low
(0.860.1 ml, n=5) (Fig. 1A). In mice without prior warfarin
treatment mice receiving i.v. rt-PA (10 mg/ml) immediately prior
to reperfusion, the degree of HT increased five-fold (4.060.5 ml,
n=5, p,0.001 compared to vehicle-treated mice) (Fig. 1A). Mice
pretreated with warfarin to an INR of approximately 3 prior to
MCAO also showed a significantly higher degree of HT
compared to control mice (4.960.5 ml, n=4, p,0.001 compared
to anticoagulation-naı ¨ve mice) (Fig. 1A). After 3 h MCAO, all
mice showed a severe neurological deficit, and no differences
between groups were observed (Fig. 1B). One mouse in the
control group and and one mouse in the warfarin group had to be
excluded due to failure of i.v. substance application (vehicle in
both cases). Corresponding mice were substituted to the operator
in a blinded fashion. Post-hoc statistical power analyses showed
an effect size (Cohen’s d) of 5.77 for the comparison of control
mice with mice receiving rt-PA and of 7.25 for the comparison of
control mice with warfarin-treated mice both providing a
statistical power of 100%.
Effective warfarin anticoagulation exacerbates the risk of
hemorrhagic transformation after rt-PA treatment
When comparing the effects of i.v. rt-PA treatment after 3 h
MCAO in non-anticoagulated mice and in mice pretreated with
oral warfarin to an INR of approximately 3, warfarin
pretreatment vastly increased the amount of HT (9.263.2 ml
vs. 2.861 ml, n=6 in both groups, p,0.05) (Fig. 2A). There was
a tendency, however non-significant, towards a more severe
neurological deficit in warfarin-treated mice that received rt-PA
as compared to mice without prior warfarin intake that received
rt-PA (median 5 vs. 4.5, p=0.1970 [Gaussian approximation])
(Fig. 2B). One mouse receiving rt-PA without prior warfarin
treatment had to be excluded due to a failure of i.v. substance
application and was substituted to the operator in a blinded
fashion. Post-hoc statistical power analyses showed an effect size
(Cohen’s d) of 4.36 for this comparison providing a statistical
power of 99%.
Rapid reversal of warfarin anticoagulation with PCC
reduces the excessive risk of hemorrhagic transformation
associated with rt-PA treatment after MCAO in
anticoagulated mice
In effectively anticoagulated mice receiving i.v. rt-PA treatment
after 3 h MCAO, the rapid reversal of anticoagulation by means
of PCC application directly prior to rt-PA administration
significantly reduced the amount of HT as compared to non
PCC-treated mice (3.860.7 ml, n=5 in all groups vs. 15.063.8 ml,
p,0.001) (Fig. 3A). Restoring the coagulation system with PCC
reduced the extent of HT to values comparable with those seen in
Figure 1. Comparison of hemorrhagic transformation 24 h
after MCAO in mice with different antithrombotic pretreat-
ment. A) Comparison of HT volumes in mice who received i.v.
thrombolysis with 10 mg/kg human recombinant t-PA directly prior to
reperfusion (middle, n=5) and mice who were effectively anticoagu-
lated to an INR of approximately 3 at the onset of 3 h MCAO (right, n=4
after exclusion of outlier, see Fig. S1) with mice who underwent 3 h
MCAO without any treatment (left, n=5). Hematoma volume was
determined by a hemoglobin assay. Data are depicted as box and
whiskers plots showing the 25 to 75 interquartile range and the
extreme values. Statistical significance was analyzed with ANOVA and
bonferroni correction for multiple testing. *** p,0.001. B) Neuroscores
were assessed for statistical significance with a Kruskal-Wallis test and
Dunn’s correction. Differences between groups were not significant
(median values 4, 4 and 5).
doi:10.1371/journal.pone.0026087.g001
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(2.861.0 ml vs. 3.860.7 ml, p=0.12, left column in Fig. 2 and
right column in Fig. 3A). In terms of neurological function, mice
whose anticoagulation was reversed with PCC showed a non-
significant tendency towards a better functional outcome (median
5 vs. 4, p=0.2738 [Gaussian approximation]) (Fig. 3B). Two mice
in the group receiving rt-PA after prior warfarin treatment without
anticoagulation reversal with PCC died due to major intracranial
hemorrhage including vast subarachnoid hemorrhage. Two mice
in the PCC-group had to be excluded due to a failure of i.v.
substance application and were substituted to the operator in a
blinded fashion. Post-hoc statistical power analyses showed an
effect size (Cohen’s d) of 7.47 for this comparison providing a
statistical power of 100%.
Prevention of excessive HT after rt-PA treatment in mice
with prior warfarin intake leads to a less severe
neurological deficit
After 1 h MCAO, leading to ischemic lesions of
49.7625.1 mm
3 in our hands (n=6, data not shown), mice with
prior warfarin treatment who received rt-PA at the onset of
reperfusion also developed a considerable degree of HT
(3.1 ml60.4, n=5 vs. 1.060.2, in control mice, n=6, p,0.001)
(Fig. 4A). Reversal of warfarin anticoagulation with PCC prior to
rt-PA treatment reduced the HT volume considerably
(1.760.3 ml, n=6, p,0.001 compared to anticoagulated and rt-
PA-treated without restoration of the coagulation system) (Fig. 4A).
In this model of milder stroke, the increase of HT in rt-PA-treated
mice with prior warfarin anticoagulation translated into a relevant
deterioration of the functional neurological outcome (median
neuroscore of 11 vs. 5 in control mice, p=0.01 [Gaussian
approximation]). Functional outcome showed a clear, however
statistically non-significant tendency to be improved in the mice
who were substituted with PCC before they received rt-PA
(median neuroscore 6, p.0.05 [Gaussian approximation])
(Fig. 4B). One mouse was excluded from the group with warfarin
pretreatment prior to rt-PA due to death secondary to an
abdominal bleeding. This mouse was not substituted to the
operator. Post-hoc statistical power analyses showed an effect size
(Cohen’s d) of 5.28 for the comparison of control mice with mice
receiving rt-PA after warfarin pretreatment providing a statistical
power of 99% and of 2.33 for the comparison of mice receiving rt-
PA after warfarin pretreatment with equally-treated mice who had
their anticoagulation reversed with PCC prior to rt-PA providing a
statistical power of 90%.
Discussion
In this experimental study, we model for the first time the
consequences of administering rt-PA in ischemic stroke occurring
under effective warfarin anticoagulation. The extent of HT after
focal cerebral ischemia is increased in mice that are under
warfarin treatment at the onset of ischemia and further potentiated
by treatment with rt-PA.
Similar to the findings of our previous experimental study [7],
we observed that mice without prior warfarin treatment develop
very little HT after 3 h MCAO, despite the evolution of large
territorial infarctions. In contrast, MCAO performed in effectively
anticoagulated mice leads to a considerable amount of HT both at
the low and the high end of the therapeutic INR range of 2–3 [7].
Since we have previously shown that the OAT-associated increase
in HT after cerebral ischemia largely depends on reperfusion [7],
we assume that the compromised coagulation system leads to a
prolongation and hence increase of microbleeds which occur
Figure 2. Hemorrhagic transformation after i.v. thrombolysis
with rt-PA is excessively increased in effectively anticoagulat-
ed mice. A) Mice without prior warfarin intake subjected to 3 h MCAO
were treated with 10 mg/kg human rt-PA directly prior to reperfusion
(left, n=5). In comparison, mice anticoagulated to an INR of
approximately 3 at the onset of cerebral ischemia (right, n=5) showed
a vast increase in hematoma volume after t-PA treatment. Statistical
significance was essayed with student’s unpaired, two-tailed t-test.
** p,0.01. B) Neuroscores were analyzed for statistical significance with
a one-tailed Mann Whitney test and the p-value given as a Gaussian
approximation (median values 4.5 and 5, p=0.1970).
doi:10.1371/journal.pone.0026087.g002
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hemispheric infarction.
Furthermore, we showed that administering rt-PA just before
reperfusion in mice without prior warfarin treatment subjected to
3 h of MCAO also leads to a significant increase of HT as
compared to untreated controls. These findings reflect the results
of clinical trials of rt-PA in stroke that show a rise in the incidence
Figure 3. Reversal of anticoagulation with PCC diminishes the
excessive rt-PA-associated risk of hemorrhagic transformation
in warfarin-treated mice. A) Anticoagulated mice treated with i.v. rt-
PA (10 mg/kg) after 3 h MCAO develop large intracerebral hematomas
(left, n=5). Reversal of oral anticoagulation with i.v. PCC (100 IU/kg)
directly before the administration of rt-PA counterbalances the
excessive risk of hemorrhagic transformation (right, n=5). Statistical
significance was essayed with student’s unpaired, two-tailed t-test.
** p,0.001. B) Neuroscores were analyzed for statistical significance
with a one-tailed Mann Whitney test and the p-value given as a
Gaussian approximation (median values 5 and 4, p=0.2738).
doi:10.1371/journal.pone.0026087.g003
Figure 4. The excessive degree of HT and the reversal of
anticoagulation with PCC are functionally relevant in a model
of milder strokes. A) Mice receiving rt-PA (10 mg/kg) after 1 h MCAO
under warfarin treatment (middle, n=5) show a significantly greater HT
volume than control mice (left, n=6). Reversal of oral anticoagulation
with PCC (100 IU/kg) significantly attenuates HT (right, n=6).
*** p,0.001. B) Functional neurological outcome was evaluated on a
14-point neuroscore and statistical significance was assessed with a
Kruskal-Wallis test with Dunn’s correction, median values are given (5,
11 and 6, ** p,0.01).
doi:10.1371/journal.pone.0026087.g004
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compared to untreated patients, although our study does not
capture hemorrhage incidence but hemorrhage volume [1]. The
increase in HT after rt-PA treatment is a well-known feature of
this drug which is due to pleiotropic properties which include the
proteolytic activation of other proteases like matrix metalloprotei-
nases (MMP, especially MMP-9) and NMDA receptor-associated
excitotoxicity [8].
Compared to non-anticoagulated animals that received rt-PA
after 3 h MCAO, mice that were effectively anticoagulated with
warfarin during this experimental paradigm revealed a signifi-
cantly higher degree of HT. Thus, whereas both effective
anticoagulation and rt-PA treatment per se increase the amount
of HT in ischemic stroke, the combination of both further
exacerbates the extent of HT. Mechanistically, the serine-protease
rt-PA catalyzes the generation of plasmin from plasminogen in a
thrombus-specific manner. This is achieved by the fibrin-
enhanceability of its enzymatic activity which leads to only a
limited conversion of plasminogen in the absence of a fibrin-rich
clot [9]. Oral anticoagulation with the vitamin K antagonist
warfarin, leading to a depletion of the vitamin K-dependent
coagulation factors II, VII, IX, and X, does not directly interfere
with the activity of rt-PA or plasmin nor does it have a direct effect
on an established thrombus [10]. Cerebral ischemia leads to a
breakdown of the blood-brain barrier that is fuelled by reperfusion
injury and administration of rt-PA [11]. We have shown
previously that reperfusion strongly determines the amount of
HT in mice who experience cerebral ischemia under effective
OAT [7]. Therefore we assume that rather than interfering
directly with the activity of rt-PA or plasminogen, the impaired
plasmatic hemostasis in case of warfarin anticoagulation leads to a
propagation of initially minor bleedings occurring at the blood-
brain barrier that is itself compromised by both ischemia/
reperfusion injury and tPA-mediated injury. Since all mice in
our model experienced some degree of HT, we cannot delineate
whether warfarin pretreatment increases the risk of HT on its own
(i.e. the de novo occurrence of HT) or just increases the volume of
bleeding.
Our results strongly support the guidelines of acute stroke
treatment who advise withholding thrombolytic treatment from
patients under effective oral anticoagulation. Clinical data from the
aforementioned study [4] of warfarin-treated patients with a
subtherapeutic INR,1.7 who were treated with i.v. thrombolysis
according to the AHA guidelines point into the same direction. In
contrast, another very recent South Korean analysis did not find a
significant influence of OAT with a subtherapeutic INR,1.7 on
the rate of symptomatic intracerebral hemorrhages after rt-PA
treatment [12]. One limitation of both studies was the small
number of 13 and 28 patients, respectively [4,12].
While investigating the potential of rapidly reversing anticoag-
ulation by PCC as a therapeutic intervention to limit the
exceeding risk of HT in anticoagulated mice receiving rt-PA in
focal cerebral ischemia, we found a strong reduction of HT to
levels comparable with those of OAT-naı ¨ve mice treated with rt-
PA. This finding further emphasizes the role of an intact plasmatic
coagulation cascade in preventing rt-PA associated HT. Whether
OAT can be safely reversed in patients with acute ischemic stroke
without provoking additional thrombus formation and vessel
occlusion has yet to be investigated. One small single-center
observational study suggests that the treatment of patients with
INR values at the lower end of the therapeutic range with fresh
frozen plasma and the subsequent catheter-based intra-arterial
thrombolysis with reteplase is possible without development of
intracranial hemorrhage in these cases. Two of the patients
experienced early neurological improvement [13]. Addressing the
widespread concern of an over-activation of the coagulation
system after anticoagulation reversal, two small observational
studies with a total of 85 non-stroke patients requiring immediate
reversal of OAT treatment have shown no activation of the
coagulation system as documented by plasma fibrinogen, D-dimer
and platelet count. However,two cases of severe thrombotic events
occurred, in one patient predisposed by a metastatic cancer and in
the other patient associated with sepsis and a beginning
disseminated intravascular coagulation [14,15]. It would be of
utmost importance to know whether it is safe to restore the
impaired plasmatic coagulation cascade in patients with ischemic
stroke occurring under OAT. This may help this group of patients
to benefit from systemic or local thrombolysis.
After 3 h MCAO, all mice typically show large territorial
infarctions leading to severe functional impairment with a median
neuroscore of 4. There was a tendency, however non-significant,
towards a more severe neurological deficit in OAT mice that
received rt-PA as compared to non-anticoagulated mice that
received rt-PA. Anticoagulated mice receiving PCC before
thrombolysis showed a tendency towards a better outcome than
OAT mice who received rt-PA without reversal of OAT but
regrettably, our study, whose primary endpoint was HT volume,
was underpowered to detect significant differences in functional
outcome in this model. To evaluate the modulation of the
functional outcome by conditions which either increase HT (i.e.,
warfarin anticoagulation) or decrease HT (i.e., anticoagulation
reversal prior to rt-PA therapy), we verified the most important
findings of our study in a model of milder stroke with a reduced
MCA occlusion time of 1 h. In this experiment, we found that the
increase in HT which was seen in the group that received rt-PA
after 1 h MCAO under warfarin-pretreatment translated into a
less favourable outcome while the substitution of PCC in this
setting did not worsen outcome but led to a strong tendency
towards a better outcome corresponding with the reduction in
HT. Since we did not assess ischemic lesion size, we cannot
exclude that the administration of PCC lead to an increase in
ischemic lesion size. However, our data on the neurological
outcome argue against functionally relevant infarct growth after
PCC treatment.
In our experiments, we used a therapeutically relevant time
window, applying rt-PA directly prior to reperfusion following 3 h
MCAO. Since rt-PA has a half-life in the circulation of
approximately five minutes [16], we assume that it is enzymatically
active when it reaches the ischemic brain area. We administered
rt-PA as a single shot because the compromised coagulation in the
warfarin-treated mice did not allow a permanent venous access
which would have been necessary for a continuous infusion over
1h .
In summary, our experimental study in mice shows that rt-PA
associated HT after focal cerebral ischemia is potentiated by prior
OAT, and therefore provides in-vivo evidence for witholding rt-
PA treatment in effectively anticoagulated patients. Reversal of
OAT with PCC might be a therapeutic option to render
recanalization therapy possible in selected patients.
Methods
Mouse model of oral anticoagulation
Male C57BL/6 mice (10 weeks old, strain J) were used in
accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (NIH Publications No. 80-
23, revised 1996). The experiments were approved by the local
governmental authorities (Regierungspraesidium Darmstadt, Ger-
Experimental Study on Thrombolysis under Warfarin
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lished protocol, we administered warfarin via oral uptake through
bottled drinking water. In brief, a 5 mg coumadin tablet (warfarin
sodium, crystalline, Bristol Myers Squibb, Munich, Germany) was
dissolved in 375 ml tap water. Assuming a body weight of 20 g
and a water consumption of 15 ml/100 g per 24 h, this dosage
corresponds to a warfarin uptake of 0.040 mg (2.00 mg/kg) per
mouse for a 24 h feeding period, a dosage which has been shown
to result in a mean INR value of 2.960.9 in our previous study
[7]. In the same study, we measured a mean INR of 0.960.1 in
non-anticoagulated mice. Details of this mouse model of oral
anticoagulation can be found elsewhere [17]. After warfarin
withdrawal, INR values remain stable for the next 6 h and drop to
normal values within 24 h. All four vitamin K dependent
coagulation factors are diminished in this mouse model, thereby
mimicking full warfarin anticoagulation [18].
Middle cerebral artery occlusion
The operator was blinded to the treatment status of the animals.
Transient middle cerebral artery occlusion (MCAO) was per-
formed as described previously [19]. Mice were anaesthetized with
1.5% isoflurane (Forene; Abbott, Wiesbaden, Germany) and
0.1 mg/kg buprenorphine (Temgesic; Essex Pharma, Munich,
Germany) under spontaneous respiration. Focal cerebral ischemia
was induced by introducing a silicone-coated 7-0 monofilament
until it occluded the ostium of the right MCA. Regional cerebral
blood flow was monitored by laser Doppler flowmetry (PF5010,
Perimed, Sweden) to confirm vessel occlusion. The filament was
withdrawn after 3 h or 1 h to allow reperfusion of the ischemic
hemisphere. Following the operation, all animals received regular
drinking water, withdrawing the warfarin supply of the previously
anticoagulated animals. Animals were sacrificed at 24 h after
assessment of their global neurological functions. Mice subjected
to the longer occlusion period of 3 h who showed a severe
neurological deficit were assessed with a 6 point neuroscore
(0=no deficit, 1=failure to extend left forepaw, 2=circling to the
left, 3=falling to the left, 4=‘‘barrel rolling’’, 5=unable to move
spontaneously, 6=dead). Mice subjected to the shorter occlusion
period of 1 h were assessed by a more differentiated 14 point
neuroscore modified from Chen et al [20]) (Table S1).
Dosing and administration of rt-PA and PCC
Human recombinant tissue plasminogen activator (rt-PA;
ActilyseH, Boehringer Ingelheim, Germany), which has been
shown to be thrombolytically active in mice at the dose of 10 mg/
kg was dissolved in aqua ad injectabilia at a concentration of
1 mg/ml and injected via the tail vein directly before reperfusion
after 3 h MCAO in reanaesthetized mice. Human PCC
(ProthromplexH 600 IE, Baxter, Vienna, Austria) was dissolved
in aqua ad injectabilia and injected via the tail vein at a dosage of
100 IU/kg directly prior to the administration of rt-PA. We have
shown previously that human PCC rapidly reverses warfarin
anticoagulation in mice [18].
Hemoglobin assay
For a quantitative analysis of HT, brains were homogenized
24 h after the induction of cerebral ischemia after transcardial
perfusion with PBS. HT blood volume was measured using a
photometric hemoglobin assay as previously described [17].
Sample size calculation and Study design
Sample size calculation was based upon our previous study
examining HT in vehicle or warfarin-treated mice subjected to the
same stroke model [7]. In this study, untreated mice had shown a
hematoma volume of 0.360.4 ml, whereas mice anticoagulated to
an INR of approximately 3 had shown a hematoma volume of
5.262.7 ml. To detect meaningful changes in a similar experi-
mental paradigm, a minimal sample size of four animals per group
is required to detect this difference with a power (1 – b) of 0.9 and
a level of acceptability of a false positive result (a) of 0.05 [21].
The study was performed in four steps. In a first step, we
evaluated the degree of HT after a 3 h MCAO period in mice that
either were on OAT or received i.v. rt-PA therapy immediately
prior to reperfusion. Furthermore, we assessed the degree of HT
after 3 h MCAO in vehicle-treated animals. 15 mice were
randomized by the allocator in a 2:1 ratio into a non-
anticoagulated group and a group anticoagulated to an INR of
approximately 3. After the MCAO procedure, the non-anticoag-
ulated mice (whose status was known to the allocator) were
injected with either rt-PA or vehicle by the operator in a blinded
fashion.
In a second step, we assessed the effect of OAT on the extent of
HT after i.v. rt-PA application immediately prior to reperfusion
after 3 h MCAO. 12 mice were randomized in a 1:1 ratio into a
non-anticoagulated group and a group anticoagulated to an INR
of approximately 3 and were operated in a blinded fashion.
In a third step, we evaluated whether the rapid reversal of
anticoagulation in OAT mice reduces the extent of HT after
treatment with i.v. rt-PA immediately prior to reperfusion after 3 h
MCAO. 10 mice were anticoagulated to an INR of approximately
3. They were randomized in a 1:1 ratio to receive either PCC or
vehicle at the end of the 3 h MCAO period, Immediately
thereafter, all mice were treated with i.v. rt-PA.
In a fourth step, we induced smaller ischemic lesions by a
shorter MCAO occlusion time of 1 h to assess the functional
impact of increased hemorrhagic transformation in less severly
impaired mice. 10 mice were anticoagulated with warfarin and
randomized in a 1:1 ratio to receive either PCC or saline
30 minutes after the onset of cerebral ischemia. Directly prior to
reperfusion, all ten mice received i.v. rt-PA. 5 mice without
warfarin or rt-PA treatment served as controls.
Our predefined exclusion criteria were 1) lack of neurological
deficit after 24 h (0 mice met this criterium), 2) death (met by 2
mice in the group of mice who received rt-PA after 3 h MCAO
under warfarin, both mice showed large intraparenchymal and
subarachnoid hemorrhages and 1 mouse in who received rt-PA
after 1 h MCAO under warfarin) and 3) failure of intravenous
application (met by 5 mice). In case of exclusion, the status of the
animal was disclosed by the allocator and an equally treated
mouse was substituted in a blinded fashion to the operator.
Statistical analyses
Graph Pad Prism 4 (Graph Pad Software Inc., La Jolla, CA,
USA) was used for statistical analysis. Results are given as mean 6
SD and graphically presented as a box and whiskers plot depicting
the mean, extreme values and the 25–75 interquartile range.
Statistical significance was assessed with a one-way ANOVA with
Bonferroni correction (multigroup analyses) and a two-tailed
student’s t-test (two-group analyses) for hematoma volume data.
For non-parametric neuroscore data, we used a Kruskal-Wallis-
test with Dunn’s correction (multigroup analyses) and a Mann
Whitney test with Gaussian approximation (two-group analyses).
In the first part of our study, we observed one value which we
suspected to be a significant outlier (Fig. S1). This was confirmed
by the Grubb’s test [22] and the outlier was excluded from the
analysis.
Experimental Study on Thrombolysis under Warfarin
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Figure S1 Exclusion of an outlier. Hemorrhagic transfor-
mation after 3 h MCAO in mice who received i.v. thrombolysis
with 10 mg/kg human recombinant t-PA directly prior to
reperfusion (middle, n=5) and mice who were effectively
anticoagulated to an INR of approximately 3 at the onset of
cerebral ischemia (right, n=5) compared to control mice with
MCAO without pretreatment (left, n=5). Hematoma volume
detected by the hemoglobin assay is given in ml for each animal.
The extreme value of 14.7 ml in the MCAO at INR 3 group was
identified as a significant outlier by the Grubb’s test and excluded
from the statistical analysis.
(TIF)
Table S1 14 point neuroscore modified from Chen et al
[20].
(DOCX)
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